secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0000875045-26-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance
--------------------------------------------------------------------------------

- Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).
- Growth products: LEQEMBI $168M (+74%), SKYCLARYS $151M (+22%), ZURZUVAE $55M (+100%), VUMERITY $179M (+29%), QALSODY $33M (+110%).
- Proposed Apellis acquisition expected to close Q2 2026, accretive in 2027; Biogen to update guidance post-close.
- FY2026 Non-GAAP EPS guidance $14.25-$15.25 (ex-Apellis); total revenue seen declining mid-single digit % vs 2025.
- Pipeline: litifilimab Phase 2 CLE positive; SPINRAZA High Dose Regimen FDA approved; felzartamab rights in Greater China acquired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/biib-20260429.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer